These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1101 related articles for article (PubMed ID: 28467925)

  • 1. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.
    Loomba R; Seguritan V; Li W; Long T; Klitgord N; Bhatt A; Dulai PS; Caussy C; Bettencourt R; Highlander SK; Jones MB; Sirlin CB; Schnabl B; Brinkac L; Schork N; Chen CH; Brenner DA; Biggs W; Yooseph S; Venter JC; Nelson KE
    Cell Metab; 2017 May; 25(5):1054-1062.e5. PubMed ID: 28467925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.
    Caussy C; Tripathi A; Humphrey G; Bassirian S; Singh S; Faulkner C; Bettencourt R; Rizo E; Richards L; Xu ZZ; Downes MR; Evans RM; Brenner DA; Sirlin CB; Knight R; Loomba R
    Nat Commun; 2019 Mar; 10(1):1406. PubMed ID: 30926798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
    Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD.
    Dong TS; Katzka W; Lagishetty V; Luu K; Hauer M; Pisegna J; Jacobs JP
    Sci Rep; 2020 Feb; 10(1):2771. PubMed ID: 32066758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.
    Oh TG; Kim SM; Caussy C; Fu T; Guo J; Bassirian S; Singh S; Madamba EV; Bettencourt R; Richards L; Yu RT; Atkins AR; Huan T; Brenner DA; Sirlin CB; Downes M; Evans RM; Loomba R
    Cell Metab; 2020 Nov; 32(5):878-888.e6. PubMed ID: 32610095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.
    Lang S; Demir M; Martin A; Jiang L; Zhang X; Duan Y; Gao B; Wisplinghoff H; Kasper P; Roderburg C; Tacke F; Steffen HM; Goeser T; Abraldes JG; Tu XM; Loomba R; Stärkel P; Pride D; Fouts DE; Schnabl B
    Gastroenterology; 2020 Nov; 159(5):1839-1852. PubMed ID: 32652145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
    Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
    Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.
    Caussy C; Hsu C; Lo MT; Liu A; Bettencourt R; Ajmera VH; Bassirian S; Hooker J; Sy E; Richards L; Schork N; Schnabl B; Brenner DA; Sirlin CB; Chen CH; Loomba R;
    Hepatology; 2018 Sep; 68(3):918-932. PubMed ID: 29572891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation.
    Maurice JB; Garvey L; Tsochatzis EA; Wiltshire M; Cooke G; Guppy N; McDonald J; Marchesi J; Nelson M; Kelleher P; Goldin R; Thursz M; Lemoine M
    AIDS; 2019 Apr; 33(5):805-814. PubMed ID: 30882489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.
    Lee G; You HJ; Bajaj JS; Joo SK; Yu J; Park S; Kang H; Park JH; Kim JH; Lee DH; Lee S; Kim W; Ko G
    Nat Commun; 2020 Oct; 11(1):4982. PubMed ID: 33020474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.
    Lang S; Farowski F; Martin A; Wisplinghoff H; Vehreschild MJGT; Krawczyk M; Nowag A; Kretzschmar A; Scholz C; Kasper P; Roderburg C; Lammert F; Goeser T; Steffen HM; Demir M
    Sci Rep; 2020 Jun; 10(1):9385. PubMed ID: 32523101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fecal mycobiome in non-alcoholic fatty liver disease.
    Demir M; Lang S; Hartmann P; Duan Y; Martin A; Miyamoto Y; Bondareva M; Zhang X; Wang Y; Kasper P; Bang C; Roderburg C; Tacke F; Steffen HM; Goeser T; Kruglov A; Eckmann L; Stärkel P; Fouts DE; Schnabl B
    J Hepatol; 2022 Apr; 76(4):788-799. PubMed ID: 34896404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis.
    Sharpton SR; Oh TG; Madamba E; Wang C; Yu RT; Atkins AR; Huan T; Downes M; Evans RM; Loomba R
    Aliment Pharmacol Ther; 2022 Nov; 56(10):1475-1485. PubMed ID: 36164267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
    Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
    Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
    Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
    Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
    Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis.
    Kannt A; Papada E; Kammermeier C; D'Auria G; Jiménez-Hernández N; Stephan M; Schwahn U; Madsen AN; Østergaard MV; Dedoussis G; Francino MP;
    Mol Nutr Food Res; 2019 Dec; 63(24):e1900927. PubMed ID: 31599067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
    Carr RM; Li Y; Chau L; Friedman ES; Lee JJ; Adorini L; Erickson M; Zaru L; Shringarpure R; MacConell L; Bittinger K; Li H; Wu GD
    Hepatology; 2023 Dec; 78(6):1843-1857. PubMed ID: 37222264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study.
    Duarte SMB; Stefano JT; Miele L; Ponziani FR; Souza-Basqueira M; Okada LSRR; de Barros Costa FG; Toda K; Mazo DFC; Sabino EC; Carrilho FJ; Gasbarrini A; Oliveira CP
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):369-384. PubMed ID: 29482963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.